Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus HALCINONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus HALCINONIDE.
ALA-CORT vs HALCINONIDE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Halcinonide is a corticosteroid that binds to glucocorticoid receptors, leading to increased synthesis of lipocortin (annexin-1), which inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA)Off-label: Atopic dermatitis, psoriasis, contact dermatitis, lichen planus, discoid lupus erythematosus
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Apply thin film topically to affected area 2 to 3 times daily.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal half-life: 4-6 hours; supports twice-daily topical dosing.
Topically applied; systemic absorption is minimal but can be increased with use on large areas, occlusive dressings, or damaged skin. Absorbed portion is metabolized primarily in the liver via hepatic microsomal enzymes (CYP3A4) and excreted by the kidneys.
Halcinonide is metabolized primarily in the liver via conjugation and hydrolysis, though specific enzymes are not well delineated. It is excreted in urine and feces.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Renal: ~50% as metabolites; biliary/fecal: ~40% as metabolites and unchanged drug.
Hydrocortisone is approximately 90–95% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin.
99% bound to albumin and corticosteroid-binding globulin (CBG).
Apparent volume of distribution (Vd) is approximately 0.4–0.6 L/kg, indicating moderate tissue distribution and limited penetration into CNS.
0.8 L/kg; indicates extensive tissue distribution.
Topical: Bioavailability is negligible (<1%) through intact skin; may increase (up to 30%) with damaged skin or occlusive dressings. Rectal: Bioavailability is approximately 10–20% via mucosal absorption, with first-pass metabolism reducing systemic exposure.
Topical: <1% (systemic); intralesional: near 100%.
No adjustment required for topical use; systemic absorption minimal.
No dose adjustment required for topical use; systemic absorption is minimal.
No adjustment required for topical use; hepatic metabolism negligible.
No dose adjustment required for topical use; systemic absorption is minimal.
Children ≥2 years: Apply a thin film to affected area 2-3 times daily. Use lowest potency preparation; avoid prolonged use.
Apply thin film topically to affected area 2 times daily; use lowest effective dose for shortest duration; avoid prolonged use.
Use lowest effective dose; monitor for skin atrophy and systemic effects due to thinner skin and increased percutaneous absorption.
Use with caution; apply thin film topically to affected area 2 times daily; avoid prolonged use due to increased risk of skin atrophy and systemic absorption.
None
None
["Systemic absorption may cause reversible HPA axis suppression","Cushing's syndrome, hyperglycemia, and glucosuria with prolonged use","Local adverse reactions: atrophy, striae, telangiectasias, acneiform eruptions, perioral dermatitis","May mask signs of infection","Use with caution in pediatric patients due to increased susceptibility to HPA axis suppression","Avoid use on face, intertriginous areas, and under occlusive dressings unless directed by physician"]
["Systemic absorption can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glycosuria.","Use with caution in patients with impaired hepatic function.","Prolonged use, use on large areas, occlusive dressings, or in children may increase systemic absorption.","Local adverse effects include skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration, secondary infection, and miliaria.","Avoid use on face, axillae, or groin unless directed by physician.","Not for ophthalmic use.","May mask signs of infection.","Use in children: may cause HPA axis suppression and growth retardation more readily than adults."]
["Hypersensitivity to any component of the formulation","Untreated bacterial, viral, fungal, or parasitic skin infections","Viral skin infections (e.g., herpes simplex, varicella) at treatment site","Perioral dermatitis","Rosacea"]
["Hypersensitivity to halcinonide or any component of the formulation","Untreated bacterial, fungal, viral, or parasitic infections at the application site","Skin ulcers or wounds"]
Data Pending Review
Data Pending Review
No known food interactions with topical ALA-CORT.
No known food interactions. However, avoid excessive alcohol consumption as it may worsen skin conditions and interfere with treatment.
FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show increased risk of cleft palate. Second/third trimester: Risk of intrauterine growth restriction, adrenal suppression in fetus. Avoid prolonged use.
Topical corticosteroids are generally considered low risk for teratogenicity when used sparingly and for short durations. Animal studies have shown cleft palate and delayed ossification with high doses of systemic corticosteroids, but no adequate human studies exist for halcinonide. First trimester: Potential risk of oral clefts with systemic use; topical use likely minimal risk. Second/third trimesters: Risk of intrauterine growth restriction and adrenal suppression with prolonged systemic use; topical use minimal risk.
Provides small amounts in breast milk; M/P ratio unknown. At maternal doses up to 80 mg/day, no adverse effects reported in infants. Consider risk-benefit with high doses or prolonged therapy.
Topical halcinonide is minimally absorbed systemically when applied to small areas, and likely presents low risk to the nursing infant. No M/P ratio available. Use with caution on nipples or large areas/occluded sites due to potential for infant exposure. Avoid application to breasts if infant may contact.
Pregnancy-induced pharmacokinetic changes (increased clearance, volume of distribution) may require increased dosing, but clinical response should guide adjustment. Avoid high doses and prolonged use.
No dose adjustments required for topical halcinonide in pregnancy. Use minimal dose for shortest duration to achieve desired effect. High-potency steroids should be avoided on large areas or for prolonged periods in pregnancy.
Category C
Category C
ALA-CORT (hydrocortisone acetate 2.5% and pramoxine HCl 1%) is a topical corticosteroid with anesthetic. Use for short-term relief of pruritus and inflammation in corticosteroid-responsive dermatoses. Avoid prolonged use on intertriginous or occluded areas. Limit to <2 weeks continuous use in adults to avoid skin atrophy. Not recommended for children <2 years.
Halcinonide is a high-potency topical corticosteroid. Limit use to 2 consecutive weeks; avoid on face, groin, axillae, or under occlusive dressings due to increased systemic absorption. Monitor for local atrophy, telangiectasias, and striae. Taper discontinuation after prolonged use to avoid rebound. Not recommended in children under 12 due to higher systemic absorption risk.
Apply a thin layer to affected area no more than 3-4 times daily.Do not cover with bandages or plastic unless directed by doctor.Avoid contact with eyes, mouth, or broken skin.Discontinue and notify doctor if infection, irritation, or no improvement after 7 days.Do not use for diaper dermatitis or under diapers/occlusive dressings.Keep out of reach of children.
Apply a thin layer only to affected areas, usually twice daily.Do not cover with bandages or plastic wrap unless directed by your doctor.Avoid using on your face, armpits, or groin unless specifically instructed.Wash hands after applying unless treating hands.Do not use for longer than prescribed, typically no more than 2 weeks.Report any signs of skin thinning, infection, or allergic reaction to your doctor.